Hengrui Medicine Stock Gains 5.9% on Novel Cancer Drug Trial Approval

Edgen Stock·Jan 05 2026, 15:05

Share to

Share to

Copy link

Key Takeaways

Hengrui Medicine's stock rose sharply after the company secured regulatory approval to begin clinical trials for a new combination therapy targeting prostate cancer. The approval covers two innovative, first-in-class drug candidates, strengthening the company's oncology pipeline and positioning it to address a market with no currently approved similar treatments.

Regulatory Milestone: Hengrui Medicine received approval from China's National Medical Products Administration for clinical trials of two new prostate cancer drugs, HRS-4357 and HRS-5041.
Positive Market Reaction: Following the announcement on January 5, the company's stock (600276.SH) climbed 5.892%.
First-in-Class Potential: The two novel drugs, developed with a combined investment of approximately ¥160.21 million, have no direct competitors on the market.

Hengrui Stock Gains 5.9% After Securing Trial Approval

Shares of Jiangsu Hengrui Pharmaceuticals (600276.SH) increased 5.892% on January 5 after the company announced it received a 'Drug Clinical Trial Approval Notice' from China's National Medical Products Administration. The approval allows Hengrui and its subsidiaries, Chengdu Shengdi Pharmaceutical and Tianjin Hengrui Pharmaceutical, to initiate clinical studies for a new combination therapy aimed at treating prostate cancer.

Company Invests Over ¥160M in Novel Drug Candidates

The upcoming trial will evaluate the combination of two proprietary drugs: HRS-4357 injection and HRS-5041 tablets. HRS-4357 is a first-in-class radiopharmaceutical therapeutic drug developed for treating PSMA-positive prostate cancer, with cumulative research and development investment reaching approximately ¥67.55 million. There are no similar drugs approved globally.

The second drug, HRS-5041, is a novel AR PROTAC (androgen receptor-protein degradation targeting chimera) small molecule designed to treat prostate cancer by degrading the AR protein. This mechanism shows potential to overcome resistance to second-generation AR inhibitors. Hengrui has invested about ¥92.66 million into the HRS-5041 program to date. Like its counterpart, no similar product has been approved for market.

New Therapy Targets Key Segment of Prostate Cancer Market

The newly approved clinical trial will specifically test the HRS-4357 and HRS-5041 combination in adult patients with prostate-specific membrane antigen (PSMA)-positive prostate cancer. By developing a therapy with a unique mechanism of action, Hengrui is positioning itself to capture a significant market segment with a high unmet medical need. A successful trial could establish a new standard of care, securing Hengrui a leadership position in advanced oncology treatments and creating a substantial new revenue stream.